A B S T R A C T The subunit structure of fibrinogen Baltimore and fibrin formed from this inherited dysfibrinogenemia was analyzed by polyacrylamide gel electrophoresis in sodium dodecyl sulfate. The molecular weights of the a-, f-and v-chains of fibrinogen Baltimore were found to be identical to those of normal fibrinogen. Noncross-linked fibrin formed from both purified fibrinogen Baltimore as well as normal fibrinogen contained two a-monomers (al and a2). a2 was presumed to be a-monomer from which fibrinopeptide A had been released. The evolution of a2 during clotting of fibrinogen Baltimore was delayed and appeared to be quantitatively reduced when compared to normal. Crosslinked fibrin formed from fibrinogen Baltimore possessed an abnormal subunit structure. a-polymers were not generated in thrombin-induced, factor XIII-rich clots of fibrinogen Baltimore under conditions of pH and calcium concentration suitable for complete a-polymerization in normal fibrin. If clotting was carried out with calcium concentrations twice that required for normal clots or at pH 6.4, fibrin from fibrinogen Baltimore was completely cross-linked. These structural analyses of fibrin formed from fibrinogen Baltimore substantiate earlier findings that indicate a defect in the a-chain of this dysfibrinogenemia.
INTRODUCTION
Fibrinogen Baltimore is an inherited dysfibrinogenemia which is different from normal fibrinogen in its relative anodal migration on immunoelectrophoresis, delayed clotting by thrombin which is partially correctable by the addition of calcium or acidification to pH 6.4, and delayed release of fibrinopeptide A (1, 2) .
A preliminary report of this work was given at the American Society of Hematology, Chicago, Ill. 1973 Studies (3, 4) of human fibrinogen and fibrin utilizing polyacrylamide gel electrophoresis in sodium dodecyl sulfate (SDS)' have revealed that normal fibrinogen consists of a-, A-and v-polypeptide subunits with mol wt of approximately 70,000, 60,000, and 50,000, respectively. Fibrin formed in the absence of activated factor XIII (fibrin-stabilizing factor) or calcium is noncross-linked and contains a-, A-, and '-monomers with molecular weights similar to those in fibrinogen, whereas fibrin formed in the presence of activated factor XIII and calcium (cross-linked fibrin) contains a-polymers (mol wt greater than 400,000), y-dimers (mol wt approximately 105,000), and P-monomers.
We have employed SDS-polyacrylamide gel electrophoresis to study the subunit structure of fibrinogen Baltimore and the fibrin formed from this fibrinogen and find that fibrinogen Baltimore exhibits an abnormal a-chain pattern and defective a-polymerization when converted to fibrin.
METHODS
Venous blood from normal donors and a patient with fibrinogen Baltimore was collected in 1/10 vol of 3.8% sodium citrate and centrifuged at 1,900 g for 30 min to prepare plasma.
Factor XIII-rich fibrinogen containing trace amounts of plasminogen was purified from 50 to 100-ml portions of plasma by the method of Kazal, Amsel, Miller, and Tocantins (5) . Plasminogen-free, factor XIII-rich fibrinogen was prepared by the method of Walker and Catlin (6) (12) . This material was approximately 12,500-fold purified compared to original plasma and was stored in lyophilized aliquots at -20'C until used. For use, purified factor XIII was reconstituted in water in a concentration approximately 20 times that in the original plasma.
Fibrin was prepared from purified fibrinogen as follows: In 13 X 75 mm siliconized glass test tubes, 0.128 ml of fibrinogen (reconstituted at a final concentration of 2 mg/ ml) was carefully adjusted to the desired pH with sodium hydroxide or hydrochloric acid, mixed with 0.064 ml of 0.02 M EDTA to prevent cross-linking or 0.064 ml of calcium chloride (final concentrations as indicated) to permit crosslinking, and clotted by the addition of thrombin (0.064 ml) at final concentrations ranging from 1.25 to 10 U/ml as indicated. To assess the effect of additional factor XIII on the subunit structure of clots formed from purified fibrinogen (already factor XIII-rich) in the presence of calcium, 0.016 ml of purified factor XIII, reconstituted for use as described above, was added to some samples before the addition of thrombin. Clots were allowed to form at 370C for periods ranging from 5 min to 24 h after which they were washed in 0.15 M sodium chloride and frozen at -20'C until analyzed.
The subunit structure of purified fibrinogen and fibrin clots were analyzed by polyacrylamide gel electrophoresis in SDS by the method of Weber and Osborn (13) 
RESULTS
Clotting of fibrinogen Baltimore. The clotting characteristics of purified fibrinogen Baltimore were similar to those for plasma from the patient with this inherited dysfibrinogenemia. Results (Table I) indicated that the fibrinogen concentration of purified specimens of fibrinogen Baltimore was measured as exceedingly low when a test based on rate of clotting (Clauss method [8] ) was used. However, when allowed to clot for 10 min in the presence of 10 U of thrombin per ml, fibrinogen Subunit structure of fibrin formed from fibrinogen Baltimore. Noncross-linked fibrin formed from purified fibrinogen Baltimore contained A-and y-monomers indistinguishable from normal (Fig. 2) . However, there were differences in the a-monomers of the fibrins formed from fibrinogen Baltimore and normal fibrinogen. In both fibrins two distinct a-monomer bands were present. These were designated a, and a2, a2 presumably having its origin from a, as a result of removal of fibrinopeptide A from the parent a-chain of fibrinogen.
In normal fibrin, a2 was more apparent than in fibrin from fibrinogen Baltimore. With high concentrations of thrombin, a2 in the abnormal fibrin became more apparent. These differences were seen regardless of the pH at which clotting was carried out and also regardless of whether or not plasminogen was present in the source of purified fibrinogen.
The subunit structures of cross-linked fibrin formed from normal fibrinogen and from fibrinogen Baltimore were markedly different (Fig. 3) . Normal fibrin was fully cross-linked (i.e., only a-polymers, y-dimers, and \Wlhen clotting wvas carried out at pH 6.4 the defect in a-polymerization that occurred at pH 7.4 was no longer apparent (Fig. 3) . Increasing the concentration of factor XIII by the addition of purified factor XIII to clotting mixtures that contained factor XIII-rich fibrinogen Baltimore failed to correct the defect in a-polymerization. It should be noted that -y-dinmerization always appeared to be normanl in the clotting of fibrinogen Baltimiore.
DISCUSSION
After its exposure to thrombin,, fibrinogen is converted to a stable fibrin clot in a step-wise manner. Three distinct reactions occur. These include first, fibrinopeptide release, then monomer aggregation. and finally polymerization or cross-linking. Fibrinopeptide release results from the cleavage by thrombin of arginyl-glycine bonds at the NH2-terminal end of the a-and A-chains of the fibrinogen molecule. The small peptide fragments removed during this reaction are designated fibrinopeptides A and B. After the release of these peptides fibrin monomers are formed which then aggregate into a gel. In the presence of calcium and activated factor XIII, covalent linking of a-chains into polymers and y-chains into dimers will occur.
Abnormalities of clotting involving any one or more of these steps have been described. Several of the inherited dysfibrinogenemias exhibit defective fibrinopeptide release and/or abnormal monomer aggregation (14) , and faulty clot stabilization exists in patients with inherited or acquired deficiences of factor XIII activity (15 We suggest, therefore, that the functional defect in fibrinogen Baltimore is the result of an abnormality of a-chain aggregation such that a-polymers are not produced under physiologic conditions. Because noncrosslinked fibrin appears to be more friable and more easily lysed bv plasmin than polymerized fibrin (16) , perhaps the hemostatic defect associated with fibrinogen Baltimore resides in its failure to produce a clot sufficiently cross-linked to resist physiologic fibrinolysis. These studies do not explain why patients with fibrinogen Baltimore may encounter the problem of recurrent thromboembolism (1) . E. A. Beck for critically reviewing the manuscript, and Dr. D. P. Jackson for assistance in planning these studies.
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